Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.44 |
| ▸ | MAOB | P27338 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20211841 | 1.00 | MAOA (0.44) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL6313868 | 0.95 | MAOA (0.46) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL20211781 | 0.85 | CYSLTR2 (0.55) | MAOAMAOBCYSLTR2CYSLTR1 | |
| SCHEMBL20211766 | 0.85 | CYSLTR2 (0.55) | MAOAMAOBCYSLTR2CYSLTR1 | |
| SCHEMBL20230313 | 0.83 | KMT2A (0.52) | NPC1RAB9ATDP1HDAC8KMT2A | |
| SCHEMBL20230319 | 0.83 | KMT2A (0.52) | NPC1RAB9ATDP1HDAC8KMT2A | |
| SCHEMBL528101 | 0.83 | MAOA (0.49) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL29856376 | 0.82 | CA12 (0.56) | MAOAMAOBTDP1 | |
| SCHEMBL20100194 | 0.82 | CA12 (0.56) | MAOAMAOBTDP1 | |
| SCHEMBL20211823 | 0.81 | PPARA (0.58) | MAOAMAOBHDAC1HDAC2CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4279490-A2 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-4279490-A2 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-3548492-B1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | PROMEGA CORP (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11192894-B2 | Cell impermeable coelenterazine analogues | PROMEGA CORPORATION (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192894-B2 | Cell impermeable coelenterazine analogues | PROMEGA CORPORATION (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200239475-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-07-30 | — | — | US | disclosed |
| US-20200239475-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-07-30 | — | — | US | disclosed |
| US-10577370-B2 | Cell impermeable coelenterazine analogues | PROMEGA CORPORATION (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577370-B2 | Cell impermeable coelenterazine analogues | PROMEGA CORPORATION (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3548492-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018102693-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018102693-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180155350-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-06-07 | — | — | US | disclosed |
| US-20180155350-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-06-07 | — | — | US | disclosed |
| US-20180155350-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192894-B2 | Cell impermeable coelenterazine analogues | SI, GLB1, MRPL21 | MAOA 4388/4885MAOB 3860/4885NPC1 239/4885 |
| US-10577370-B2 | Cell impermeable coelenterazine analogues | SI, GLB1, MRPL21 | MAOA 4388/4885MAOB 3860/4885NPC1 239/4885 |
| US-20200239475-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | SI, GLB1, MRPL21 | MAOA 4388/4885MAOB 3860/4885NPC1 239/4885 |
| US-20180155350-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | SI, GLB1, MRPL21 | MAOA 4388/4885MAOB 3860/4885NPC1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.